Judge Strikes Down Trump’s Plan for Drug Prices
Prescription drug cost has been a heated topic for many years. The cost is outrageous and continues to skyrocket among the cost of living. This is a terrible situation because it is almost cheaper to die than it is to stay alive on medicines which are needed for some people to function or even live.
When Obamacare came into the picture, it made things ten times worse for families because they could not afford the cost of the premiums much less the medicine they had to purchase. This is why Trump has done away with the majority of Obamacare.
The FDA can be one of the most crooked of all because people need some of these medicines, and they would rather a person suffer or die than to push for a lower cost. Why? Because they along with pharmaceuticals pocket the money.
Many politicians have claimed to have tried to get the FDA to lower the cost, but they never did anything about it. President Trump is the only president in our lifetime who has ever made campaign promises while working to get elected and stick to his guns. He may not have gotten to everything he said he was going to do, but he is working to get the job done.
The American people have pleaded with the president to do something to get the FDA and pharmaceuticals to lower the cost of prescriptions. Here is the problem. Democrats run the healthcare division, and they own an investment with the FDA and Obamacare. This is what is taking so long. Everything President Trump has to do is an uphill battle from the decades of corruption.
Monday was no different on climbing up that mountain to lower prescriptions. President Trump was working to get drug makers and the FDA to have the price of the drugs included in the ads they set forth. A federal judge blocked the rule and stated The White House does not have the legal authority to push for the disclosure of prices within their TV ads.
The U.S. District Judge Amit Mehta struck down the rule which was to become law on Tuesday. Drugmakers claimed forcing them to show the list prices were a violation of the Constitution under The First Amendment.
Judge Mehta put out a 27-page ruling which did not debate the violation of Freedom of Speech. The ruling stated the Trump administration did not show they had enough evidence or the legal grounds to force such a rule to disclose prices. In his own words, “Neither the law’s text, structure, nor context evince an intent by Congress to empower (administrative agencies) to issue a rule that compels drug manufacturers to disclose list prices.”
Without coming out right and admitting it, the judge suggested the Trump administration may be right through the merits. He refused to question the motives of the Health and Human Services Department. They are the ones who would have issued the rule. The judge wrote, “That policy very well could be an effective tool in halting the rising cost of prescription drugs. But no matter how vexing the problem of spiraling drug costs may be, HHS cannot do more than what Congress has authorized. The responsibility rests with Congress to act in the first instance.”
Caitlin Oakley, an HHS spokeswoman, expressed the disappointment by the judges ruling, stating, “We are disappointed by the ruling and will be working with the Department of Justice on next steps related to the litigation.” There are two ways they can go about this. One way is to appeal the decision in court. The other way is a snowball chance in hell. They could request Congress to require the prices to be disclosed by the drug makers.
However, there may be a glimmer of hope since The Senate is Conservative owned. The House and Senate are both working together to come up with a package deal to lower the cost of health care for patients who are insured. The price of prescription drugs is on the list of topics. Keep in mind, Democrats still own a vestment in Obamacare and the FDA. They will not give up.
Nancy LeaMond, who is the Vice President of AARP, stated, “Today’s ruling is a step backward in the battle against skyrocketing drug prices. Americans should be trusted to evaluate drug price information and discuss any concerns with their health care providers.”
One more mention, Judge Mehta was put on the bench by Obama.